Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC

Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC

Introduction: To assess the technical feasibility and safety of repeated percutaneous computed tomography (CT)–guided transthoracic biopsies and intratumoral injections of gene-modified dendritic cells in metastatic NSCLC. Methods: A total of 15 patients with 15 NSCLC lesions measuring greater than...

Full description

Bibliographic Details
Main Authors:	Puja Shahrouki, MD, Jay M. Lee, MD, Jonathan Barclay, MD, Sarah N. Khan, MD, Scott Genshaft, MD, Fereidoun Abtin, MD, Steven M. Dubinett, MD, Aaron Lisberg, MD, Sherven Sharma, PhD, Edward B. Garon, MD, Robert Suh, MD
Format:	Article
Language:	English
Published:	Elsevier 2021-11-01
Series:	JTO Clinical and Research Reports
Subjects:	Dendritic cells Non–small cell lung cancer Gene therapy Immunotherapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364321001016

Similar Items

Dendritic Cells (DCs)-Based Cancer Immunotherapy: A Review on the Prospects of Medicinal Plants and Their Phytochemicals as Potential Pharmacological Modulators
by: Md. Selim Ahmed, et al.
Published: (2022-09-01)

Substance P promotes immunotherapy efficacy for airway allergy
by: Yongjin Wu, MD, et al.
Published: (2023-01-01)

Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060
by: Takehiro Tozuka, MD, et al.
Published: (2024-04-01)

CCL21 Cancer Immunotherapy
by: Yuan Lin, et al.
Published: (2014-05-01)

The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis
by: Merle I. Ronden, MD, et al.
Published: (2021-07-01)

Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report
by: Mariona Riudavets, PhD, et al.
Published: (2022-05-01)

Surgical Complexity of Pulmonary Resections Performed for Oligometastatic NSCLC
by: Mara B. Antonoff, MD, et al.
Published: (2022-03-01)

Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects
by: Lysanne A. Lievense, MD, PhD, et al.
Published: (2023-01-01)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
by: Saro Kasparian, MD, et al.
Published: (2020-06-01)

Targeting MET in NSCLC: An Ever-Expanding Territory
by: Ying Han, MD, et al.
Published: (2024-02-01)

Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC
by: Ezgi B. Ulas, BSc, et al.
Published: (2023-09-01)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
by: Ryo Toyozawa, MD, et al.
Published: (2020-03-01)

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
by: Kalijn F. Bol, et al.
Published: (2019-04-01)

Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC
by: Ferréol Roborel de Climens, MD, et al.
Published: (2021-05-01)

Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC—Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy
by: Takehito Shukuya, MD, PhD, et al.
Published: (2022-05-01)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
by: Yuki Takeyasu, MD, et al.
Published: (2022-05-01)

Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2023-06-01)

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
by: Zoran Andric, MD, et al.
Published: (2023-02-01)

Long-Term Recurrence of Completely Resected NSCLC
by: Katsuhiro Masago, MD, PhD, et al.
Published: (2020-09-01)

LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC
by: Marliese Alexander, B.Pharm(Hons), MPH, PhD, et al.
Published: (2023-04-01)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
by: Joshua E. Reuss, MD, et al.
Published: (2021-10-01)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
by: Véronique Hofman, MD, PhD, et al.
Published: (2023-02-01)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
by: Ying Cheng, MD, et al.
Published: (2021-10-01)

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants
by: Kazumi Nishino, MD, PhD, et al.
Published: (2024-02-01)

Anaplastic oligodendroglioma presenting with apoplectic intratumoral hemorrhage
by: Kohei Yoshida, MD, et al.
Published: (2023-02-01)

Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC
by: Farrah B. Khan, MD, et al.
Published: (2024-03-01)

Underutilization of Systemic Therapy in Patients With NSCLC Undergoing Pneumonectomy: A Missed Opportunity for Survival
by: Jorge Humberto Rodriguez-Quintero, MD, et al.
Published: (2023-08-01)

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
by: Yuki Takeyasu, MD, et al.
Published: (2024-02-01)

A novel peanut allergy immunotherapy: Plant-based enveloped Ara h 2 Bioparticles activate dendritic cells and polarize T cell responses to Th1
by: Charlotte Castenmiller, MSc, et al.
Published: (2023-11-01)

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
by: Aaron S. Mansfield, MD, et al.
Published: (2021-08-01)

The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis
by: Lye-Yeng Wong, MD, et al.
Published: (2024-03-01)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
by: Alissa J. Cooper, MD, et al.
Published: (2022-09-01)

Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
by: Shengxiang Ren, MD, et al.
Published: (2022-05-01)

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
by: Kiichiro Ninomiya, MD, PhD, et al.
Published: (2021-01-01)

Unusual Resistance Mechanisms in a Case of ROS1-Rearranged NSCLC: A Case Report
by: Ullas Batra, MD, et al.
Published: (2022-03-01)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
by: Jingran Ji, MD, et al.
Published: (2023-03-01)

Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study
by: Hayato Kawachi, MD, et al.
Published: (2022-07-01)

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
by: Hidetoshi Hayashi, MD, PhD, et al.
Published: (2023-04-01)

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes
by: Anne-Marie Ruppert, MD, PhD, et al.
Published: (2020-09-01)

Systemic and intratumoral 9-valent human papillomavirus vaccine treatment for squamous cell carcinoma in situ in a renal transplant recipient
by: Anna J. Nichols, MD, PhD, et al.
Published: (2020-04-01)